loadpatents
Patent applications and USPTO patent grants for Opalinska; Joanna.The latest application filed is for "combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof".
Patent | Date |
---|---|
Combination treatment for cancer with anti-BCMA binding protein and proteosome inhibitor Grant 11,401,334 - Khandekar , et al. August 2, 2 | 2022-08-02 |
Combination Treatments For Cancer Comprising Belantamab Mafodotin And An Anti Ox40 Antibody And Uses And Methods Thereof App 20220098303 - Biswas; Swethajit ;   et al. | 2022-03-31 |
Belantamab Mafodotin In Combination With Pembrolizumab For Treating Cancer App 20220096650 - OPALINSKA; Joanna | 2022-03-31 |
Methods Of Treating Cancer App 20220003772 - DETTMAN; Elisha J. ;   et al. | 2022-01-06 |
Combination Treatment For Cancer App 20200270354 - KHANDEKAR; Sanjay ;   et al. | 2020-08-27 |
Combination Treatment For Cancer App 20200255526 - Kind Code | 2020-08-13 |
Combination Treatment For Cancer App 20200254093 - Kind Code | 2020-08-13 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.